The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

John H. Stewart named center director of LSU Health New Orleans/LCMC Health Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

John H. Stewart was named center director of the LSU Health New Orleans/LCMC Health Cancer Center. 

He will also join the LSU Health New Orleans School of Medicine faculty as a professor of surgery.

Stewart will set the overall mission, vision and direction for multidisciplinary cancer care and cancer clinical research programs for LSU Health New Orleans and LCMC Health in his new leadership role. 

He and his team will develop a robust cancer clinical trials program, leverage resources to build an innovative targeted cancer research enterprise and create a comprehensive community outreach and engagement program to reduce cancer risk behaviors and cancer incidence. 

Initiatives will integrate disease-specific research and care delivery into a comprehensive patient-oriented approach to benefit patients of Louisiana and surrounding regions, including those currently underserved in accessing leading-edge cancer care.

Stewart, originally from Shreveport, was recruited from the University of Illinois College of Medicine in Chicago. There, he was a University of Illinois Presidential Scholar, professor of surgery in the College of Medicine, deputy director of the University of Illinois Cancer Center, and physician executive for oncology sciences at the University of Illinois Health.

Stewart’s role will be effective July 1.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account